Getagraph.com logo
NASDAQ Composite: ( -0.01%) 16 735
S&P 500
(0.80%) 5 277.51 points
Dow Jones
(1.51%) 38 686 points
Nasdaq
(-0.01%) 16 735 points
Oil
(-0.94%) $77.18
Gas
(0.35%) $2.58
Gold
(-0.79%) $2 347.70
Silver
(-3.10%) $30.56
Platinum
(0.63%) $1 044.50
USD/EUR
(-0.17%) $0.921
USD/NOK
(-0.49%) $10.49
USD/GBP
(-0.05%) $0.785
USD/RUB
(0.15%) $90.40

Realtime updates for Amicus Therapeutics Inc [FOLD]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
83.33%
return 4.80%
SELL
42.86%
return 2.61%
Last Updated31 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

-0.81% $ 9.80

BUY 154325 min ago

@ $13.20

Issued: 14 Feb 2024 @ 15:36

Return: -25.76%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 1.62 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):
Profile picture for Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data...

Stats
Today's Volume 2.36M
Average Volume 2.84M
Market Cap 2.90B
EPS $0 ( 2024-05-09 )
Next earnings date ( $0 ) 2024-08-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -20.00
ATR14 $0.0120 (0.12%)
Insider Trading
Date Person Action Amount type
2024-05-01 Campbell Bradley L Buy 7 500 Common Stock
2024-05-01 Campbell Bradley L Sell 7 500 Common Stock
2024-05-01 Campbell Bradley L Sell 7 500 Stock Options (right to buy)
2024-04-15 Prout Samantha Sell 7 027 Common Stock
2024-04-01 Campbell Bradley L Buy 7 500 Common Stock
INSIDER POWER
17.12
Last 100 transactions
Buy: 1 721 174 | Sell: 1 181 964

Volume Correlation

Long: -0.20 (neutral)
Short: -0.53 (weak negative)
Signal:(47.846) Neutral

Amicus Therapeutics Inc Correlation

10 Most Positive Correlations
SHLS0.951
IART0.931
QLGN0.929
TXG0.928
ALGT0.927
ARKO0.924
SFIX0.916
GLPG0.915
APVO0.914
JAKK0.914
10 Most Negative Correlations
PNTG-0.922
AEYE-0.921
PPC-0.918
ENTX-0.916
FRLA-0.912
VITL-0.912
RDNT-0.909
MDWD-0.907
RZLT-0.906
JAN-0.905

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amicus Therapeutics Inc Correlation - Currency/Commodity

The country flag 0.08
( neutral )
The country flag 0.29
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.09
( neutral )
The country flag -0.08
( neutral )

Amicus Therapeutics Inc Financials

Annual 2023
Revenue: $399.36M
Gross Profit: $354.16M (88.68 %)
EPS: $-0.510
FY 2023
Revenue: $399.36M
Gross Profit: $354.16M (88.68 %)
EPS: $-0.510
FY 2022
Revenue: $329.23M
Gross Profit: $290.63M (88.28 %)
EPS: $-0.820
FY 2021
Revenue: $305.51M
Gross Profit: $271.05M (88.72 %)
EPS: $-0.920

Financial Reports:

No articles found.

Amicus Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 1.5580399036407 seconds
Number of API calls: 2
Number of DB calls: 8